JP2014501762A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501762A5 JP2014501762A5 JP2013546407A JP2013546407A JP2014501762A5 JP 2014501762 A5 JP2014501762 A5 JP 2014501762A5 JP 2013546407 A JP2013546407 A JP 2013546407A JP 2013546407 A JP2013546407 A JP 2013546407A JP 2014501762 A5 JP2014501762 A5 JP 2014501762A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- adult
- peptide
- item
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims description 19
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 19
- 230000003442 weekly effect Effects 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 125000003827 glycol group Chemical group 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims description 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010033307 Overweight Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 239000000883 anti-obesity agent Substances 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 229940125708 antidiabetic agent Drugs 0.000 claims description 2
- 229940125710 antiobesity agent Drugs 0.000 claims description 2
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 claims description 2
- 208000004104 gestational diabetes Diseases 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000004584 weight gain Effects 0.000 claims description 2
- 235000019786 weight gain Nutrition 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 26
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 17
- 102100040918 Pro-glucagon Human genes 0.000 description 17
- 239000000556 agonist Substances 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426338P | 2010-12-22 | 2010-12-22 | |
| US61/426,338 | 2010-12-22 | ||
| US201161500229P | 2011-06-23 | 2011-06-23 | |
| US61/500,229 | 2011-06-23 | ||
| PCT/US2011/066739 WO2012088379A2 (en) | 2010-12-22 | 2011-12-22 | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014501762A JP2014501762A (ja) | 2014-01-23 |
| JP2014501762A5 true JP2014501762A5 (enExample) | 2015-02-12 |
Family
ID=46314922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546407A Pending JP2014501762A (ja) | 2010-12-22 | 2011-12-22 | Ｇｉｐおよびｇｌｐ−１受容体活性グルカゴン系ペプチドにより代謝障害および肥満を治療するための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8975223B2 (enExample) |
| EP (1) | EP2654774A4 (enExample) |
| JP (1) | JP2014501762A (enExample) |
| KR (1) | KR20140020851A (enExample) |
| CN (1) | CN103402536A (enExample) |
| AR (1) | AR084558A1 (enExample) |
| AU (1) | AU2011348202A1 (enExample) |
| BR (1) | BR112013015861A2 (enExample) |
| CA (1) | CA2822617A1 (enExample) |
| MX (1) | MX2013007327A (enExample) |
| NZ (1) | NZ611878A (enExample) |
| RU (1) | RU2013133803A (enExample) |
| SG (1) | SG191252A1 (enExample) |
| WO (1) | WO2012088379A2 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2528618A4 (en) * | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| RU2739209C2 (ru) | 2011-06-10 | 2020-12-21 | Ханми Сайенс Ко., Лтд. | Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения |
| SI2721062T1 (sl) | 2011-06-17 | 2019-03-29 | Hanmi Science Co., Ltd. | Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega |
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| WO2013041678A1 (en) | 2011-09-23 | 2013-03-28 | Novo Nordisk A/S | Novel glucagon analogues |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| US9724420B2 (en) | 2012-11-06 | 2017-08-08 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region |
| ES2828505T3 (es) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| SG10202100667SA (en) | 2012-12-27 | 2021-02-25 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| RU2683039C2 (ru) | 2013-04-18 | 2019-03-26 | Ново Нордиск А/С | Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения |
| HUE057361T2 (hu) * | 2013-05-28 | 2022-05-28 | Takeda Pharmaceuticals Co | Peptid vegyület |
| WO2015035419A1 (en) * | 2013-09-09 | 2015-03-12 | Hoffmann-La Roche Inc. | Dosages of gip/glp-1 co-agonist peptides for human administration |
| CN105792851B (zh) * | 2013-09-13 | 2023-10-10 | 斯克利普斯研究所 | 修饰的治疗剂及其组合物 |
| EP3062881B1 (en) | 2013-10-28 | 2019-10-02 | NGM Biopharmaceuticals, Inc. | Cancer models and associated methods |
| US10626156B2 (en) | 2013-12-06 | 2020-04-21 | Jie Han | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| AU2014364589B2 (en) | 2013-12-18 | 2020-02-27 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| NZ722377A (en) | 2014-01-24 | 2022-09-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| TW201625669A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー／エス | 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト |
| US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2016020119A1 (en) * | 2014-08-06 | 2016-02-11 | Nestec S.A. | Biomarkers for predicting degree of weight loss |
| US10968266B2 (en) | 2014-09-05 | 2021-04-06 | University Of Copenhagen | GIP peptide analogues |
| TWI802396B (zh) * | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| CN107108711B (zh) | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| MX382408B (es) | 2014-10-24 | 2025-03-13 | Merck Sharp & Dohme Llc | Coagonistas de los receptores de glucagón y de glp-1. |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| KR101669140B1 (ko) | 2015-04-28 | 2016-10-26 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| EA201891946A1 (ru) * | 2016-03-10 | 2019-04-30 | Медиммун Лимитед | Коагонисты глюкагона и glp-1 для лечения ожирения |
| WO2017204219A1 (ja) | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | ペプチド化合物 |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| CN109200273B (zh) * | 2017-07-04 | 2021-02-19 | 中国药科大学 | 一种多肽用于制备预防或治疗脂肪肝病药物的用途 |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| CN110691788B (zh) * | 2017-05-31 | 2024-05-31 | 哥本哈根大学 | 长效gip肽类似物 |
| US10470311B2 (en) * | 2017-09-28 | 2019-11-05 | Juniper Networks, Inc. | Clearance size reduction for backdrilled differential vias |
| KR20200069316A (ko) | 2017-10-12 | 2020-06-16 | 노보 노르디스크 에이/에스 | 의료 요법에서의 세마글루타이드 |
| CN112074531B (zh) * | 2018-05-04 | 2025-04-15 | 诺和诺德股份有限公司 | Gip衍生物及其用途 |
| CA3107344A1 (en) * | 2018-07-23 | 2020-01-30 | Eli Lilly And Company | Methods of using a gip/glp1 co-agonist for therapy |
| KR20210102911A (ko) | 2018-12-03 | 2021-08-20 | 안타그 테라퓨틱스 에이피에스 | 변형된 gip 펩티드 유사체 |
| CN109379770B (zh) * | 2018-12-11 | 2021-04-06 | 北京百瑞互联技术有限公司 | 蓝牙mesh网络的路径辅助候选节点的优选方法、装置及节点 |
| WO2020143625A1 (zh) * | 2019-01-07 | 2020-07-16 | 鸿绪生物医药科技（北京）有限公司 | 新型多肽及其治疗用途 |
| WO2021083306A1 (zh) * | 2019-10-31 | 2021-05-06 | 东莞市东阳光生物药研发有限公司 | Glp-1/gcg双受体激动剂多肽 |
| AU2021304762B2 (en) * | 2020-07-06 | 2024-05-02 | Vitalixir (Beijing) Co., Ltd | Novel polypeptide and therapeutic use thereof |
| TW202214679A (zh) * | 2020-07-22 | 2022-04-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及gip受體共促效劑 |
| CN116157143A (zh) * | 2020-07-22 | 2023-05-23 | 诺和诺德股份有限公司 | 适合于口服递送的glp-1和gip受体的共激动剂 |
| MX2023001599A (es) * | 2020-08-14 | 2023-03-07 | Hanmi Pharmaceutical Co Ltd | Composicion farmaceutica que comprende un conjugado de accion prolongada del triple agonista del receptor de glucagon/glp-1/gip. |
| KR20220050820A (ko) * | 2020-10-16 | 2022-04-25 | 한미약품 주식회사 | Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 |
| WO2022117056A1 (zh) * | 2020-12-02 | 2022-06-09 | 南京明德新药研发有限公司 | 含内酰胺修饰的多肽类化合物 |
| CN114891071A (zh) * | 2020-12-08 | 2022-08-12 | 鸿绪生物科技(嘉善)有限公司 | 新型多肽及其治疗用途 |
| CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| CA3220005A1 (en) | 2021-05-13 | 2022-11-17 | Carmot Therapeutics Inc. | Modulators of g-protein coupled receptors |
| AU2022289610A1 (en) * | 2021-06-09 | 2024-01-25 | The Scripps Research Institute | Long-acting dual gip/glp-1 peptide conjugates and methods of use |
| CN118103391A (zh) * | 2021-11-12 | 2024-05-28 | 福建盛迪医药有限公司 | Glp-1受体和gip受体双重激动剂的药物组合物及其用途 |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN116712530B (zh) * | 2023-02-03 | 2024-03-08 | 江苏师范大学 | 一类长效GLP-1/glucagon/GIP受体三重激动剂及其应用 |
| WO2024226540A1 (en) * | 2023-04-23 | 2024-10-31 | Carmot Therapeutics Inc. | Treatment of diabetes mellitus |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| BRPI0815416A2 (pt) | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| EA020326B9 (ru) | 2008-06-17 | 2015-03-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения |
| CN102325539A (zh) | 2008-12-19 | 2012-01-18 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
| CN102459325B (zh) | 2009-06-16 | 2015-03-25 | 印第安纳大学科技研究有限公司 | 胃抑胜肽受体活化的胰高血糖素化合物 |
| EP2528618A4 (en) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| BR112013015389A2 (pt) | 2010-12-22 | 2016-11-22 | Univ Indiana Res & Tech Corp | análogo de glucagon exibindo atividade de receptor gip |
-
2011
- 2011-12-22 AR ARP110104906A patent/AR084558A1/es unknown
- 2011-12-22 US US13/996,937 patent/US8975223B2/en not_active Expired - Fee Related
- 2011-12-22 BR BR112013015861A patent/BR112013015861A2/pt not_active IP Right Cessation
- 2011-12-22 NZ NZ611878A patent/NZ611878A/en not_active IP Right Cessation
- 2011-12-22 CA CA2822617A patent/CA2822617A1/en not_active Abandoned
- 2011-12-22 CN CN2011800619016A patent/CN103402536A/zh active Pending
- 2011-12-22 EP EP11851411.6A patent/EP2654774A4/en not_active Withdrawn
- 2011-12-22 RU RU2013133803/15A patent/RU2013133803A/ru not_active Application Discontinuation
- 2011-12-22 KR KR1020137019021A patent/KR20140020851A/ko not_active Withdrawn
- 2011-12-22 AU AU2011348202A patent/AU2011348202A1/en not_active Abandoned
- 2011-12-22 WO PCT/US2011/066739 patent/WO2012088379A2/en not_active Ceased
- 2011-12-22 JP JP2013546407A patent/JP2014501762A/ja active Pending
- 2011-12-22 SG SG2013047402A patent/SG191252A1/en unknown
- 2011-12-22 MX MX2013007327A patent/MX2013007327A/es not_active Application Discontinuation
-
2015
- 2015-02-10 US US14/618,580 patent/US20160175400A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014501762A5 (enExample) | ||
| RU2013133803A (ru) | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп | |
| JP2010031018A5 (enExample) | ||
| JP5552046B2 (ja) | インスリン誘導体を含有する薬学的製剤 | |
| CN103665148B (zh) | 一种可口服给药的降糖多肽及其制法和用途 | |
| JP6755175B2 (ja) | インスリン投薬レジメン | |
| Choe et al. | Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists | |
| JP2012505852A5 (enExample) | ||
| TW201127395A (en) | Pharmaceutical composition comprising a GLP-1 agonist and methionine | |
| CA2798518A1 (en) | Pegylated c-peptide | |
| KR20130092972A (ko) | 인슐린-아연 복합체의 제조 방법 | |
| JP2016516016A5 (enExample) | ||
| JP2016516076A5 (enExample) | ||
| EP3268029B1 (en) | Treatment of type 2 diabetes mellitus patients | |
| JP2018531938A5 (enExample) | ||
| US20130096048A1 (en) | Treatment of sepsis and septic shock using ghrelin and growth hormone | |
| IL291681B2 (en) | Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease | |
| JP2020514305A5 (enExample) | ||
| CN102552883A (zh) | 一种多肽复合物、药物组合物、其制备方法和应用 | |
| EP4587045A2 (en) | Therapeutic regimens and methods for reducing body weight in a subject with fatty liver disease using a glp-1r and gcgr agonist | |
| JP6049625B2 (ja) | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 | |
| JP2006514665A5 (enExample) | ||
| CN107847560A (zh) | 包括eno1的组合物以及其在治疗肥胖症或超重和减少体重增加的方法中的用途 | |
| US20110183926A1 (en) | Treatment using continuous low dose application of sugar analogs | |
| CN102988282A (zh) | 一种改善断奶仔猪肠道发育的针剂溶液的配制方法 |